Bora Pharmaceuticals Q2 2026 EPS beats estimates, revenue falls short

Bora Pharmaceuticals Ltd. reported second-quarter 2026 earnings per share that exceeded analyst expectations, though revenue fell short of projections, according to a transcript of its earnings call.

The company posted adjusted earnings per share of $0.45, topping the $0.42 consensus estimate compiled by Bloomberg. Revenue for the quarter totaled $112.3 million, missing the $118.7 million forecast.

Management attributed the revenue shortfall to weaker-than-expected demand in key markets and supply chain disruptions that delayed shipments. Despite the revenue miss, Bora highlighted strong pricing power in its specialty pharmaceutical products, which helped offset some of the pressure.

Chief Executive Officer Chen Wen-hsiung noted that the company remains focused on expanding its contract development and manufacturing organization (CDMO) business, a segment expected to drive future growth. He added that Bora is on track to meet its full-year 2026 revenue guidance of $480 million to $500 million, though the company did not revise its guidance following the quarterly results.

Analysts at JPMorgan maintained a neutral rating on Bora’s shares, citing the revenue miss as a near-term concern but acknowledging the earnings beat as a positive sign. The stock was last trading 2.1% lower in extended-hours trading following the release.

Bora Pharmaceuticals, headquartered in Taiwan, specializes in the development and manufacturing of generic and biosimilar drugs. The company serves markets in North America, Europe, and Asia.